Diagnosis and Treatment

The Society of Critical Care Medicine recommends intravenous hydrocortisone at doses <400 mg/day for ≥3 days for patients with septic shock that is not responsive to fluid and moderate to high-dose vasopressor therapy, with a conditional recommendation and low quality evidence 1, 2, 3
The European Society of Intensive Care Medicine suggests that plasma total cortisol is preferred over plasma free cortisol or salivary cortisol for diagnosis, with a conditional recommendation and very low quality evidence 3
Clinical signs and symptoms of CIRCI include hypotension refractory to fluid resuscitation, decreased sensitivity to catecholamines, fever, confusion, and persistent hypoxia, with laboratory findings such as hypoglycemia, hyponatremia, hyperkalemia, and metabolic acidosis 1, 4

Treatment Recommendations by Condition

For septic shock not responsive to fluid and moderate to high-dose vasopressor therapy, the Surviving Sepsis Campaign recommends intravenous hydrocortisone <400 mg/day for ≥3 days at full dose, with a conditional recommendation and low quality evidence 2, 4, 5
For early moderate to severe Acute Respiratory Distress Syndrome (ARDS), the Society of Critical Care Medicine suggests IV methylprednisolone 1 mg/kg/day, with a conditional recommendation and moderate quality evidence 2, 3
For hospitalized patients with Community-Acquired Pneumonia (CAP), the Infectious Diseases Society of America recommends corticosteroids for 5-7 days at a daily dose <400 mg IV hydrocortisone or equivalent, with a conditional recommendation and moderate quality evidence 6

Perioperative Management

For patients with known adrenal insufficiency undergoing major surgery, the American Society of Anesthesiologists recommends hydrocortisone 100 mg IV on induction, followed by continuous infusion of hydrocortisone 200 mg/24h, with postoperative continuation of IV infusion while nil by mouth, then double oral hydrocortisone doses for 48h or up to a week following major surgery 4, 7

Monitoring and Adverse Effects

The Society of Critical Care Medicine recommends monitoring for potential adverse effects of corticosteroid therapy, including hyperglycemia, hypernatremia, secondary infections, gastrointestinal bleeding, and psychiatric effects, with regular blood pressure determinations and serum electrolyte monitoring 4, 5

Treatment Recommendations by Condition

For septic shock not responsive to fluid and moderate to high-dose vasopressor therapy, the Society of Critical Care Medicine recommends using IV hydrocortisone <400 mg/day for ≥3 days at full dose, with a long course and low dose preferred over high dose and short course 8, 9
The European Society of Intensive Care Medicine suggests that corticosteroids are not recommended for patients with sepsis without shock, as the HYPRESS trial showed no difference in rates of progression to septic shock or mortality with hydrocortisone versus placebo 10
For early moderate to severe Acute Respiratory Distress Syndrome (ARDS), the American Thoracic Society recommends using IV methylprednisolone 1 mg/kg/day, with a preference for methylprednisolone due to its greater penetration into lung tissue and longer residence time 11
The Society of Critical Care Medicine advises that corticosteroids are not recommended for patients with major trauma, as analysis of 19 trials showed no significant effect on mortality (RR 1.00, 95% CI 0.89-1.13) 11, 12
The American Heart Association suggests that corticosteroids may be beneficial in the setting of cardiac arrest, with studies showing improved rates of return to spontaneous circulation and better neurological outcomes at hospital discharge 13

Administration Guidelines

When administering corticosteroids for CIRCI, the Endocrine Society recommends tapering slowly (6-14 days) rather than stopping abruptly to avoid rebound inflammation, with a strength of evidence rated as high 11

Special Considerations

The Infectious Diseases Society of America recommends infection surveillance during corticosteroid treatment, as it blunts the febrile response, with a strength of evidence rated as moderate 11

Common Pitfalls

The Society of Critical Care Medicine warns that abrupt discontinuation of corticosteroids can lead to deterioration from a reconstituted inflammatory response, with a strength of evidence rated as high 11

Hydrocortisone Dosage for Acute Conditions

Condition-Specific Dosing

The Society of Critical Care Medicine and European Society of Intensive Care Medicine recommend 200 mg/day of IV hydrocortisone for septic shock not responsive to fluid and moderate to high-dose vasopressor therapy, administered either as divided doses or as a continuous infusion 14, 15
Corticosteroids should not be used for sepsis without shock, as recommended by the Society of Critical Care Medicine and European Society of Intensive Care Medicine 14, 15

Duration of Treatment

For septic shock, treatment with hydrocortisone should continue for at least 3 days at full dose, as recommended by the Society of Critical Care Medicine and European Society of Intensive Care Medicine 14
Tapering of hydrocortisone is recommended when vasopressors are no longer required rather than stopping abruptly, as suggested by the European Society of Intensive Care Medicine 15

Common Pitfalls to Avoid

Using corticosteroids in sepsis without shock is not recommended and provides no benefit, according to the Society of Critical Care Medicine and European Society of Intensive Care Medicine 14, 15
The use of the adrenocorticotropic hormone stimulation test to identify patients with septic shock who should receive hydrocortisone is not recommended by the European Society of Intensive Care Medicine 15

Adverse Effects of Solucortef (Hydrocortisone) IV

Hypersensitivity Reactions

Mild hypersensitivity reactions to Solucortef (hydrocortisone) IV can manifest as pruritus, flushing, urticaria, and chest tightness, according to the American Journal of Hematology 16
Moderate hypersensitivity reactions can include transient cough, shortness of breath, tachycardia, and mild hypotension, as reported by the American Journal of Hematology 16, 17
Severe or life-threatening hypersensitivity reactions, such as anaphylaxis, can occur with Solucortef (hydrocortisone) IV administration, characterized by sudden onset and rapid intensification of symptoms, loss of consciousness, severe hypotension, angioedema of tongue/airway, and involvement of multiple organ systems, as described by the American Journal of Hematology 16, 17

Long-term Adverse Effects

Long-term use of Solucortef (hydrocortisone) IV can lead to ocular effects, including cataracts and glaucoma, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 18

Management of Adverse Effects

In cases of hypersensitivity reactions, the American Journal of Hematology recommends stopping the infusion immediately if signs of reaction occur 16, 17
For mild reactions, monitoring for at least 15 minutes and considering antihistamines for urticaria are recommended by the American Journal of Hematology 16, 17
In severe reactions or anaphylaxis, administration of epinephrine 0.3 mg IM into the anterolateral thigh is advised by the American Journal of Hematology 16
The American Journal of Hematology also suggests providing oxygen if hypoxemic, administering IV fluids for hypotension, and considering albuterol nebulizer for bronchospasm in cases of severe reactions or anaphylaxis 16, 17

Prevention of Adverse Effects

Using the lowest effective dose for the shortest duration possible can help prevent adverse effects, as suggested by Blood Advances 19

Corticosteroid Treatment in Critical Illness

Tapering and Monitoring Considerations

In cases where infliximab or other immunosuppressants are used concurrently, a shorter taper may help minimize infection complications, according to the Journal of the National Comprehensive Cancer Network 20
For patients with immune-related adverse events receiving corticosteroids, checking response after 2-3 days is recommended to determine if additional immunosuppressants are needed, as suggested by the Journal of the National Comprehensive Cancer Network 20

Hydrocortisone Tapering in Septic Shock

Recommended Tapering Protocol

The American College of Critical Care Medicine recommends tapering hydrocortisone gradually over 6-14 days when vasopressors are no longer required, rather than stopping abruptly, to avoid rebound inflammation and hemodynamic deterioration 21
The initial treatment duration should be at least 5 days at full dose before initiating a taper, according to the Critical Care society 22

Critical Monitoring During Taper

Monitor serum sodium levels for hypernatremia, as recommended by the Critical Care Medicine society 21

Common Pitfalls to Avoid

The Critical Care Medicine society advises against using the ACTH stimulation test to guide tapering decisions—it has no role in determining when or how to taper 21
Be aware that etomidate use prior to hydrocortisone initiation may worsen outcomes, as noted by the Critical Care Medicine society 21

Steroid Tapering in Septic Shock

Introduction to Steroid Tapering

The Surviving Sepsis Campaign and SCCM/ESICM guidelines suggest tapering hydrocortisone when vasopressors are discontinued (Grade 2D recommendation) 23, 24
Steroids should be tapered when vasopressors are no longer required, rather than stopped abruptly, to avoid hemodynamic and immunologic rebound effects 23, 24

Recommended Tapering Approach

The American College of Critical Care Medicine recommends maintaining full-dose hydrocortisone for at least 3-5 days before initiating taper 25, 26
The taper should be started when vasopressors are no longer required 23, 24

Evidence Quality and Nuances

The recommendation for tapering is based on weak evidence (Grade 2D) 23, 24
No direct comparative studies exist between tapering versus abrupt cessation, or between fixed-duration versus clinically-guided regimens 23, 24

Key Supporting Evidence

One crossover study demonstrated hemodynamic and immunologic rebound effects after abrupt cessation 23, 24, 27
The Society of Critical Care Medicine suggests monitoring for hyperglycemia (blood glucose) during tapering 23, 28

Common Considerations

The European Society of Intensive Care Medicine recommends avoiding abrupt discontinuation of steroids, as it can lead to deterioration from reconstituted inflammatory response 23
The use of etomidate prior to hydrocortisone may worsen outcomes, according to the American College of Critical Care Medicine 23
The Intensive Care Medicine society recommends not using steroids in sepsis without shock, as no benefit has been demonstrated 25, 26

Corticosteroid Use in Critically Ill Patients

Condition-Specific Guidelines

For early moderate-to-severe Acute Respiratory Distress Syndrome (ARDS), the American Thoracic Society recommends using IV methylprednisolone 1 mg/kg/day for ≥14 days, as it has greater penetration into lung tissue and longer residence time, with a recent meta-analysis confirming reduced short-term mortality 29
For hospitalized patients with Community-Acquired Pneumonia (CAP), the Infectious Diseases Society of America suggests using corticosteroids for 5-7 days at a daily dose <400 mg IV hydrocortisone or equivalent, with a meta-analysis of 13 trials showing reduced hospital stay, decreased need for mechanical ventilation, and prevented ARDS 29
The Society of Critical Care Medicine conditionally recommends using corticosteroids in patients undergoing cardiopulmonary bypass surgery, with an analysis of 14 trials finding a reduced risk of mortality (RR 0.84, 95% CI 0.70-1.01) 29
The American College of Chest Physicians advises against using corticosteroids in adults with influenza, as an analysis of 13 observational studies found an increased risk of death (OR 3.06, 95% CI 1.58-5.92) and increased risk of superinfection 29
The World Health Organization notes that early evidence from SARS and MERS showed no clear benefit and potential harm with corticosteroids, with a meta-analysis of SARS treatment reporting possible harm and a multi-center study of MERS showing delayed viral clearance and lack of survival benefit 30

Hydrocortisone Dosing for Hypotension

Clinical Context Determines Dosing

The American Society of Anesthesiologists recommends giving 100 mg IV hydrocortisone immediately without waiting for diagnostic confirmation if the patient is unstable with volume-resistant hypotension, followed by maintenance dosing of 200 mg/24 hours as continuous infusion or 50 mg IV every 6 hours in patients with adrenal crisis or suspected adrenal insufficiency 31, 32
The American Society of Anesthesiologists suggests never delaying treatment for diagnostic procedures in suspected adrenal crisis—mortality is high if untreated, and recommends continuing full-dose therapy for at least 3-5 days before considering a taper 33

Perioperative Hypotension

The American College of Surgeons recommends hydrocortisone 100 mg IV at induction, followed immediately by continuous infusion of 200 mg/24 hours, and continuing IV infusion while nil by mouth or if postoperative vomiting occurs in patients with known adrenal insufficiency 31, 32
The American College of Surgeons suggests resuming oral dosing at double the usual replacement dose for 48 hours after uncomplicated surgery, or up to one week following major surgery 31, 32

Critical Dosing Principles

The American Society of Health-System Pharmacists recommends a standard initial dose of 100 mg IV hydrocortisone for acute situations, and suggests that doses exceeding usual dosages may be justified in overwhelming, acute, life-threatening situations 31, 32
The American Society of Health-System Pharmacists recommends continuous infusion of 200 mg/24 hours or divided doses of 50 mg IV every 6 hours for maintenance dosing, with a total daily dose range of 100-300 mg/day depending on severity 31

Corticosteroides para Hipotensión Refractaria

Indicaciones y Uso

En niños con shock séptico refractario a catecolaminas, la Sociedad de Cuidados Críticos recomienda considerar hidrocortisona 1 mg/kg cada 6 horas (dosis pediátrica de estrés) 34
Para hipotensión resistente a vasopresores que puede atribuirse a insuficiencia suprarrenal, se sugiere considerar dosis de estrés de hidrocortisona solamente, evitando dosis altas de corticosteroides linfocitotóxicos (dexametasona o metilprednisolona), según la Sociedad de Cuidados Intensivos 35
La norepinefrina es el vasopresor de primera línea; los corticosteroides se agregan cuando la hipotensión persiste, según la Sociedad de Medicina Crítica 36

Pruebas Diagnósticas y Decisión de Tratamiento

La prueba de estimulación con ACTH (250 μg) no debe utilizarse para identificar qué pacientes con shock séptico deben recibir hidrocortisona, según la Sociedad de Medicina Intensiva 37
El ensayo CORTICUS demostró respuesta hemodinámica similar a corticosteroides en pacientes con o sin insuficiencia suprarrenal crítica documentada, lo que sugiere que la decisión de tratar debe basarse en criterios clínicos, como la presión arterial baja que responde mal a vasopresores a pesar de reanimación adecuada con líquidos, según la Sociedad de Medicina Intensiva 37

Hydrocortisone Use in Non‑Septic Distributive Shock – Guideline Evidence

Recommendations from Septic‑Shock Guidelines (Context)

The SCCM/ESICM 2017 guideline recommends hydrocortisone only for septic shock that remains hypotensive despite adequate fluid resuscitation and moderate‑to‑high dose vasopressors, using a dose < 400 mg/day IV for at least 3 days. 38
The same SCCM/ESICM 2017 guideline states that hydrocortisone should not be used in distributive shock that is responsive to vasopressors because no benefit has been demonstrated. 38
The SCCM/ESICM 2017 guideline advises against routine prophylactic hydrocortisone in any form of distributive shock. 38

Evidence Gap for Non‑Septic Distributive Shock

The Critical Care Medicine 2013 guideline explicitly addresses only septic shock, highlighting a critical knowledge gap and the absence of high‑quality trials for hydrocortisone in non‑septic distributive shock. [39][40]38

Clinical Criteria for Considering Hydrocortisone in Non‑Septic Shock

According to the Critical Care Medicine 2013 guideline, hydrocortisone may be considered in non‑septic distributive shock only when:
A random cortisol level < 18 µg/dL in a patient with shock suggests absolute adrenal insufficiency and supports the use of hydrocortisone (Critical Care Medicine 2013). 39

Diagnostic and Therapeutic Pitfalls

The Critical Care Medicine 2013 guideline recommends not using ACTH stimulation testing to guide hydrocortisone therapy because it does not predict response and delays treatment. [39][40]
The same guideline cautions against high‑dose, short‑course hydrocortisone regimens; only low‑dose, prolonged therapy has shown potential benefit in septic shock. 39

Monitoring for Adverse Effects

The SCCM/ESICM 2017 guideline reports that hyperglycemia is the most common adverse effect of hydrocortisone and requires regular blood‑glucose monitoring. 38